Badrinath Konety

Personal Home Page

http://urology.ucsf.edu/faculty/facKonety.html

Articles in Scholarly Journals [Incomplete List]

  1. Treatment failure after primary and salvage therapy for prostate cancer
    Cancer, vol. 112, no. 2, pp. 307–314, 2008
  2. Active surveillance for the management of prostate cancer in a contemporary cohort
    Cancer, vol. 112, no. 12, pp. 2664–2670, 2008
  3. A Model That Predicts the Probability of Positive Imaging in Prostate Cancer Cases With Biochemical Failure After Initial Definitive Local Therapy
    The Journal of Urology, vol. 179, no. 3, pp. 906–910, 2008
  4. Patterns of Primary and Secondary Therapy for Prostate Cancer in Elderly Men: Analysis of Data From CaPSURE®
    The Journal of Urology, vol. 179, no. 5, pp. 1797–1803, 2008
  5. Commentary on the Etiologic Relationship Between Prostate Radiation and Bladder Cancer: The Scourge for One is Poison for the Other
    The Journal of Urology, vol. 179, no. 5, pp. S12–S13, 2008
  6. Editorial Comment
    The Journal of Urology, vol. 180, no. 1, pp. 162–163, 2008
  7. Editorial Comment
    The Journal of Urology, vol. 180, no. 3, pp. 828–829, 2008
  8. Editorial Comment
    The Journal of Urology, vol. 180, no. 3, pp. 891–891, 2008
  9. Sickness and Survival in Bladder Cancer: Is Comorbidity the Crystal Ball?
    European Urology, vol. 53, no. 3, pp. 465–467, 2008
  10. Screening and Management of Prostate Cancer in Elderly Men: The Iowa Prostate Cancer Consensus
    Urology, vol. 71, no. 3, pp. 511–514, 2008
  11. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression
    Nature Clinical Practice Urology, vol. 5, no. 5, Article ID ncpuro1058, 6 pages, 2008
  12. Should men over the age of 65 years receive PSA screening? Argument in favor
    Nature Clinical Practice Urology, vol. 5, no. 5, Article ID ncpuro1078, 1 pages, 2008
  13. Urothelial bladder cancer: biomarkers for detection and screening
    BJU International, vol. 102, no. 9b, pp. 1234–1241, 2008
  14. Interview with Dr Badrinath Konety
    Aging Health, vol. 4, no. 5, pp. 447–449, 2008
  15. Specificity of Procedure Volume and In-hospital Mortality Association
    Annals of Surgery, vol. 246, no. 1, pp. 135–139, 2007
  16. Personality, treatment choice and satisfaction in patients with localized prostate cancer
    International Journal of Urology, vol. 14, no. 11, pp. 1013–1018, 2007
  17. Does periprostatic nerve block with local anesthetic reduce pain during prostate biopsy?
    Nature Clinical Practice Urology, vol. 4, no. 2, Article ID ncpuro0678, 1 pages, 2007
  18. The optimal management of clinically localized prostate cancer: the debate continues
    Nature Clinical Practice Urology, vol. 4, no. 9, Article ID ncpuro0880, 1 pages, 2007
  19. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancerWachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, Mitterhauser M, Dobrozemsky G, Li S, Pötter R, Dudczak R, Kletter K, Departments of Nuclear Medicine, Radiotherapy, and Urology and Clinical Division of Oncology, Department of Medicine I, Hospital Pharmacy of the General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
    Urologic Oncology: Seminars and Original Investigations, vol. 25, no. 1, pp. 90–90, 2007
  20. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomyRosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ, Division of Urology, University of Florida, Jacksonville, FL
    Urologic Oncology: Seminars and Original Investigations, vol. 25, no. 1, pp. 90–91, 2007
  21. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trialWallace K, Fleshner N, Jewett M, Basiuk J, Crook J, Department of Radiation Medicine and the Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Urologic Oncology: Seminars and Original Investigations, vol. 25, no. 1, pp. 91–92, 2007
  22. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomyWeckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R, Department of Urology, Klinikum Augsburg, Augsburg, Germany
    Urologic Oncology: Seminars and Original Investigations, vol. 25, no. 1, pp. 92–92, 2007
  23. Incidence of initial local therapy among men with lower-risk prostate cancer in the United StatesMiller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT, Department of Urology, University of Michigan, Ann Arbor, MI
    Urologic Oncology: Seminars and Original Investigations, vol. 25, no. 1, pp. 92–93, 2007
  24. Factors affecting outcomes after radical cystectomy in African Americans
    Cancer, vol. 109, no. 3, pp. 542–548, 2007
  25. PSA Screening and Elderly Men--Reply
    JAMA: The Journal of the American Medical Association, vol. 297, no. 9, pp. 949–949, 2007
  26. Influence of Post-Cystectomy Complications on Cost and Subsequent Outcome
    The Journal of Urology, vol. 177, no. 1, pp. 280–287, 2007
  27. Bladder Cancer Incidence and Risk Factors in Men With Prostate Cancer: Results From Cancer of the Prostate Strategic Urologic Research Endeavor
    The Journal of Urology, vol. 177, no. 3, pp. 883–888, 2007
  28. Recovery of Urinary Continence Following Radical Prostatectomy: The Impact of Prostate Volume—Analysis of Data From the CaPSURE™ Database
    The Journal of Urology, vol. 177, no. 4, pp. 1423–1426, 2007
  29. Analysis of Complications Following Partial and Total Nephrectomy for Renal Cancer in a Population Based Sample
    The Journal of Urology, vol. 177, no. 5, pp. 1709–1714, 2007
  30. Bladder and Upper Tract Urothelial Cancer
    The Journal of Urology, vol. 177, no. 5, pp. 1636–1645, 2007
  31. Editorial Comment
    The Journal of Urology, vol. 178, no. 2, pp. 528–528, 2007
  32. Trends in Regionalization of Inpatient Care for Urological Malignancies, 1988 to 2002
    The Journal of Urology, vol. 178, no. 5, pp. 2103–2108, 2007
  33. Editorial Comments
    The Journal of Urology, vol. 178, no. 6, pp. 2301–2301, 2007
  34. PSA Screening Among Elderly Men With Limited Life Expectancies
    JAMA: The Journal of the American Medical Association, vol. 296, no. 19, pp. 2336–2342, 2006
  35. Bladder Cancer Preventionâ??Could a Carrot Be the Stick?
    The Journal of Urology, vol. 176, no. 3, pp. 864–865, 2006
  36. Editorial Comment
    The Journal of Urology, vol. 176, no. 6, pp. 2481–2481, 2006
  37. Quality of life in long-term survivors of bladder cancer
    Cancer, vol. 106, no. 11, pp. 2355–2362, 2006
  38. Characteristics of patients and predictors of in-hospital mortality after hospitalization for head and neck cancers
    Cancer, vol. 106, no. 11, pp. 2382–2388, 2006
  39. Cutaneous metastases from transitional cell carcinoma of the bladder
    Urology, vol. 67, no. 4, pp. 846.e15–846.e17, 2006
  40. Complications after radical cystectomy: Analysis of population-based data
    Urology, vol. 68, no. 1, pp. 58–64, 2006
  41. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer
    Urology, vol. 68, no. 1, pp. 121–125, 2006
  42. Practice patterns in screening and management of prostate cancer in elderly men
    Urology, vol. 68, no. 5, pp. 1051–1056, 2006
  43. Prevalence of Prostate Specific Antigen Testing for Prostate Cancer in Elderly Men
    The Journal of Urology, vol. 175, no. 6, pp. 2078–2082, 2006
  44. Editorial comment
    The Journal of Urology, vol. 175, no. 1, pp. 67–68, 2006
  45. The Impact of Age on the Response of Patients With Superficial Bladder Cancer to Intravesical Immunotherapy
    The Journal of Urology, vol. 175, no. 5, pp. 1634–1640, 2006
  46. Percutaneous radiofrequency ablation of renal tumors: Technique, complications, and outcomesAhrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME, The Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 1, pp. 85–86, 2006
  47. Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intentMcDougal WS, Gervais DA, McGovern FJ, Mueller PR, Department of Urology, The Massachusetts General Hospital and the Harvard Medical School, Boston, MA
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 1, pp. 86–86, 2006
  48. Fibrin glue v sutured bolster: Lessons learned during 100 laparoscopic partial nephrectomiesJohnston WK III, Montgomery JS, Seifman BD, Hollenbeck BK, Wolf SJ Jr, Michigan Urology Center, University of Michigan, Ann Arbor, MI
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 1, pp. 88–88, 2006
  49. Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: A study and reviewLawrentschuk N, Gani J, Riordan R, Esler S, Bolton DM, Surgery and Urology, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 1, pp. 84–85, 2006
  50. Renal cryoablation: Outcome at 3 yearsGill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, Kaouk JH, Desai MM, Novick AC, Section of Laparoscopic and Minimally Invasive Surgery, Glickman Urological Institute and Department of Radiology, Cleveland Clinic Foundation, Cleveland, OH
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 1, pp. 86–87, 2006
  51. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification systemLam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS, Division of Urologic Oncology, the Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 1, pp. 87–88, 2006
  52. Molecular markers in bladder cancer: A critical appraisal
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 4, pp. 326–337, 2006
  53. Complete response of bony metastatic bladder urothelial cancer to neoadjuvant chemotherapy and cystectomy
    Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 5, pp. 403–406, 2006
  54. Clinical Protocol: Phase I Study of an Adenovirus/Prostate-Specific Antigen Vaccine in Men with Metastatic Prostate Cancer
    Human Gene Therapy, vol. 17, no. 2, pp. 220–229, 2006
  55. Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?
    BJU International, vol. 97, no. 1, pp. 48–50, 2006
  56. Prostate-specific antigen testing in the elderly: a hard habit to kick?
    BJU International, vol. 97, no. 1, pp. 4–5, 2006
  57. Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/ -Catenin Signaling Pathway
    Clinical Cancer Research, vol. 12, no. 2, pp. 383–391, 2006
  58. Mortality After Major Surgery for Urologic Cancers in Specialized Urology Hospitals: Are They Any Better?
    Journal of Clinical Oncology, vol. 24, no. 13, pp. 2006–2012, 2006
  59. The prevalence of renal cell carcinoma diagnosed at autopsy
    BJU International, vol. 95, no. 1, pp. 31–33, 2005
  60. IMPACT OF HOSPITAL AND SURGEON VOLUME ON IN-HOSPITAL MORTALITY FROM RADICAL CYSTECTOMY: DATA FROM THE HEALTH CARE UTILIZATION PROJECT
    The Journal of Urology, vol. 173, no. 5, pp. 1695–1700, 2005
  61. IMPACT OF MALPRACTICE CAPS ON USE AND OUTCOMES OF RADICAL CYSTECTOMY FOR BLADDER CANCER: DATA FROM THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM
    The Journal of Urology, vol. 173, no. 6, pp. 2085–2089, 2005
  62. THE IMPACT OF PROVIDER VOLUME ON OUTCOMES FROM UROLOGICAL CANCER THERAPY
    Journal of Urology, The, vol. 174, no. 2, pp. 432–438, 2005
  63. COMPARISON OF THE INCIDENCE OF LATENT PROSTATE CANCER DETECTED AT AUTOPSY BEFORE AND AFTER THE PROSTATE SPECIFIC ANTIGEN ERA
    The Journal of Urology, vol. 174, no. 5, pp. 1785–1788, 2005
  64. Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: Impact on patient outcomes and costs
    Urology, vol. 65, no. 3, pp. 488–492, 2005
  65. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: Retrospective analysis of the National Surveillance, Epidemiology, and End Results database
    Urology, vol. 65, no. 4, pp. 675–680, 2005
  66. Use of bipolar power source for transurethral resection of bladder tumor in patient with implanted pacemaker
    Urology, vol. 66, no. 1, pp. 194–194, 2005
  67. Effect of axillary lymphadenectomy on breast carcinoma survival
    Breast Cancer Research and Treatment, vol. 91, no. 1, pp. 11–18, 2005
  68. Squamous cell carcinoma of the penis
    Cancer, vol. 101, no. 6, pp. 1357–1363, 2004
  69. Prostate cancer screening parameters in a high-risk African-Caribbean population*1
    Urology, vol. 63, no. 4, pp. 737–741, 2004
  70. Testicular recurrence from ?primary? retroperitoneal germ cell tumor
    Urology, vol. 64, no. 5, pp. 1031–1031, 2004
  71. Feasibility of Radical Prostatectomy After Neoadjuvant Chemohormonal Therapy for Patients With High Risk or Locally Advanced Prostate Cancer: Results of a Phase I/II Study
    The Journal of Urology, vol. 171, no. 2, pp. 709–713, 2004
  72. IS A NERVE (GRAFT) STILL A NERVE BY ANY OTHER NAME?
    The Journal of Urology, vol. 172, no. 1, pp. 10–11, 2004
  73. ASSOCIATION BETWEEN VOLUME AND CHARGES FOR MOST FREQUENTLY PERFORMED AMBULATORY AND NONAMBULATORY SURGERY FOR BLADDER CANCER. IS MORE CHEAPER?
    The Journal of Urology, vol. 172, no. 3, pp. 1056–1061, 2004
  74. HEALTH RELATED QUALITY OF LIFE ASSESSMENTS FOR PATIENTS WITH BLADDER CANCER
    The Journal of Urology, vol. 172, no. 6, pp. 2130–2136, 2004
  75. Functional Characterization of the Bladder Cancer Marker, BLCA-4
    Clinical Cancer Research, vol. 10, no. 4, pp. 1384–1391, 2004
  76. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder
    BJU International, vol. 94, no. 1, pp. 18–21, 2004
  77. Use of Bipolar Energy for Transurethral Resection of Bladder Tumors: Pathologic Considerations
    Journal of Endourology, vol. 18, no. 6, pp. 578–582, 2004
  78. Long-term treatment of metastatic renal-cell carcinoma with fluorouracil
    The Lancet Oncology, vol. 5, no. 11, pp. 690–692, 2004
  79. Fluorescence cystoscopy and bladder surveillance
    Current Opinion in Urology, vol. 14, no. 5, pp. 265–270, 2004
  80. Extent of Pelvic Lymphadenectomy and Its Impact On Outcome in Patients Diagnosed With Bladder Cancer: Analysis of Data From the Surveillance, Epidemiology and End Results Program Data Base
    The Journal of Urology, vol. 169, no. 3, pp. 946–950, 2003
  81. Factors Influencing Aggressive Therapy for Bladder Cancer: An Analysis of Data From the SEER Program
    The Journal of Urology, vol. 170, no. 5, pp. 1765–1771, 2003
  82. Surgical Enucleation for the Treatment of Renal Tumors
    Urologia Internationalis, vol. 71, no. 2, pp. 184–189, 2003
  83. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis
    Urology, vol. 62, no. 6, pp. 1083–1088, 2003
  84. Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D3 (calcitriol) using a microdialysis technique
    Urology, vol. 59, no. 6, pp. 947–952, 2002
  85. Vitamin D and prostate cancer
    Urologic Clinics of North America, vol. 29, no. 1, pp. 95–106, 2002
  86. RE: URINE BASED MARKERS OF UROLOGICAL MALIGNANCY
    The Journal of Urology, vol. 167, no. 3, pp. 1407–1407, 2002
  87. RE: URINE BASED MARKERS OF UROLOGICAL MALIGNANCY
    The Journal of Urology, pp. 1406–1407, 2002
  88. EFFECTS OF VITAMIN D (CALCITRIOL) ON TRANSITIONAL CELL CARCINOMA OF THE BLADDER IN VITRO AND IN VIVO
    The Journal of Urology, vol. 165, no. 1, pp. 253–258, 2001
  89. URINE BASED MARKERS OF UROLOGICAL MALIGNANCY
    The Journal of Urology, vol. 165, no. 2, pp. 600–611, 2001
  90. NONANDROGENIC MEDIATORS OF PROSTATIC GROWTH
    Hematology/Oncology Clinics of North America, vol. 15, no. 3, pp. 459–476, 2001
  91. Recurrent metastatic renal cell carcinoma presenting as a bleeding gastric ulcer after a complete response to high-dose interleukin-2 treatment
    Urology, vol. 57, no. 1, p. 168, 2001
  92. Urolume stent placement for the treatment of postbrachytherapy bladder outlet obstruction
    Urology, vol. 55, no. 5, pp. 721–724, 2000
  93. Evaluation of the effect of spinal cord injury on serum PSA levels
    Urology, vol. 56, no. 1, pp. 82–86, 2000
  94. IN VITRO AND IN VIVO EFFECTS OF VITAMIN D (CALCITRIOL) ADMINISTRATION ON THE NORMAL NEONATAL AND PREPUBERTAL PROSTATE
    The Journal of Urology, vol. 164, no. 5, pp. 1812–1818, 2000
  95. CLINICAL USEFULNESS OF THE NOVEL MARKER BLCA-4 FOR THE DETECTION OF BLADDER CANCER
    The Journal of Urology, vol. 164, no. 3, pp. 634–639, 2000
  96. Effect of prenatal vitamin D (calcitriol) exposure on the growth and development of the prostate
    The Prostate, vol. 41, no. 3, pp. 181–189, 1999
  97. HEPATOCELLULAR CARCINOMA METASTATIC TO THE BLADDER AFTER LIVER TRANSPLANTATION
    The Journal of Urology, vol. 162, no. 3, pp. 799–800, 1999
  98. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture1
    Urology, vol. 54, no. 1, pp. 171–177, 1999
  99. Advantages and risks of ileovesicostomy for the management of neuropathic bladder
    Urology, vol. 54, no. 4, pp. 636–640, 1999
  100. Diagnostic Value of Voided Urine and Bladder Barbotage Cytology in Detecting Transitional Cell Carcinoma of the Urinary Tract
    Urologia Internationalis, vol. 62, no. 1, pp. 26–30, 1999
  101. EMBRYONAL ADENOMA OF THE KIDNEY ASSOCIATED WITH POLYCYTHEMIA AND VON WILLEBRAND DISEASE
    The Journal of Urology, vol. 160, no. 6, pp. 2171–2174, 1998
  102. IDENTIFICATION OF NUCLEAR MATRIX PROTEIN ALTERATIONS ASSOCIATED WITH RENAL CELL CARCINOMA
    The Journal of Urology, vol. 159, no. 4, pp. 1359–1363, 1998
  103. Association of vitamin D receptors with the nuclear matrix of human and rat genitourinary tissues
    The Journal of Steroid Biochemistry and Molecular Biology, vol. 66, no. 4, pp. 241–246, 1998
  104. Prostate cancer in the post-transplant population
    Urology, vol. 52, no. 3, pp. 428–432, 1998
  105. Perineural invasion in transitional cell carcinoma and the effect on prognosis following radical cystectomy
    Urology, vol. 49, no. 6, pp. 968–972, 1997
  106. Botryoid rhabdomyosarcoma of the bladder
    Urology, vol. 50, no. 4, pp. 604–605, 1997
  107. Vitamin d inhibition of prostate adenocarcinoma growth and metastasis in the dunning rat prostate model system
    Urology, vol. 50, no. 6, pp. 999–1006, 1997
  108. A cost containment strategy for radical retropubic prostatectomy: Results from implementation of a clinical pathway program
    Urologic Oncology: Seminars and Original Investigations, vol. 2, no. 3, pp. 80–87, 1996
  109. Simultaneous radical nephrectomy and repair of abdominal aortic aneurysm
    Urology, vol. 47, no. 6, pp. 813–818, 1996
  110. Cystic teratoma of the ovary mimicking a bladder stone
    Urology, vol. 48, no. 3, pp. 466–467, 1996
  111. Evaluation of computerized tomography for staging of clinically localized adenocarcinoma of the prostate
    Urologic Oncology: Seminars and Original Investigations, vol. 2, no. 1, pp. 14–19, 1996
  112. Ureteral Entrapment in the Sacroiliac Joint in Pelvic Trauma
    The Journal of Trauma: Injury, Infection, and Critical Care, vol. 40, no. 1, pp. 150–151, 1996
  113. Scrotal Elephantiasis Associated with Hidradenitis Suppurative
    Plastic & Reconstructive Surgery, vol. 97, no. 6, pp. 1243–1245, 1996
  114. Neuroanatomy of the External Urethral Sphincter: Implications for Urinary Continence Preservation During Radical Prostate Surgery
    The Journal of Urology, vol. 153, no. 2, pp. 337–341, 1995
  115. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: Detection via localized proton spectroscopy
    Urology, vol. 45, no. 3, pp. 459–466, 1995